Logo image of MSGS

MADISON SQUARE GARDEN SPORTS (MSGS) Stock Fundamental Analysis

NYSE:MSGS - US55825T1034 - Common Stock

195.78 USD
-2.06 (-1.04%)
Last: 9/2/2025, 8:20:12 PM
196.47 USD
+0.69 (+0.35%)
Pre-Market: 9/3/2025, 5:01:40 AM
Fundamental Rating

2

Overall MSGS gets a fundamental rating of 2 out of 10. We evaluated MSGS against 79 industry peers in the Entertainment industry. MSGS has a bad profitability rating. Also its financial health evaluation is rather negative. MSGS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MSGS had negative earnings in the past year.
MSGS had a positive operating cash flow in the past year.
In multiple years MSGS reported negative net income over the last 5 years.
MSGS had a positive operating cash flow in 4 of the past 5 years.
MSGS Yearly Net Income VS EBIT VS OCF VS FCFMSGS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M -300M

1.2 Ratios

MSGS has a Return On Assets (-1.52%) which is in line with its industry peers.
With a Return On Invested Capital value of 1.25%, MSGS perfoms like the industry average, outperforming 59.49% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for MSGS is significantly below the industry average of 20.67%.
The 3 year average ROIC (7.74%) for MSGS is well above the current ROIC(1.25%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA -1.52%
ROE N/A
ROIC 1.25%
ROA(3y)2.11%
ROA(5y)1.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.74%
ROIC(5y)N/A
MSGS Yearly ROA, ROE, ROICMSGS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

1.3 Margins

Looking at the Operating Margin, with a value of 1.42%, MSGS is in line with its industry, outperforming 56.96% of the companies in the same industry.
In the last couple of years the Operating Margin of MSGS has declined.
MSGS has a Gross Margin of 33.84%. This is in the lower half of the industry: MSGS underperforms 60.76% of its industry peers.
MSGS's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 1.42%
PM (TTM) N/A
GM 33.84%
OM growth 3Y-48.58%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.62%
GM growth 5Y-3.48%
MSGS Yearly Profit, Operating, Gross MarginsMSGS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40

More info and screens

3

2. Health

2.1 Basic Checks

MSGS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
MSGS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MSGS remains at a similar level compared to 5 years ago.
The debt/assets ratio for MSGS has been reduced compared to a year ago.
MSGS Yearly Shares OutstandingMSGS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
MSGS Yearly Total Debt VS Total AssetsMSGS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

An Altman-Z score of 1.96 indicates that MSGS is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of MSGS (1.96) is better than 64.56% of its industry peers.
MSGS has a debt to FCF ratio of 3.31. This is a good value and a sign of high solvency as MSGS would need 3.31 years to pay back of all of its debts.
MSGS has a Debt to FCF ratio of 3.31. This is in the better half of the industry: MSGS outperforms 77.22% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.31
Altman-Z 1.96
ROIC/WACC0.15
WACC8.58%
MSGS Yearly LT Debt VS Equity VS FCFMSGS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

MSGS has a Current Ratio of 0.45. This is a bad value and indicates that MSGS is not financially healthy enough and could expect problems in meeting its short term obligations.
MSGS has a worse Current ratio (0.45) than 81.01% of its industry peers.
A Quick Ratio of 0.45 indicates that MSGS may have some problems paying its short term obligations.
MSGS has a Quick ratio of 0.45. This is in the lower half of the industry: MSGS underperforms 79.75% of its industry peers.
Industry RankSector Rank
Current Ratio 0.45
Quick Ratio 0.45
MSGS Yearly Current Assets VS Current LiabilitesMSGS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

3

3. Growth

3.1 Past

MSGS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -137.86%.
Looking at the last year, MSGS shows a small growth in Revenue. The Revenue has grown by 1.18% in the last year.
MSGS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.49% yearly.
EPS 1Y (TTM)-137.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-106.6%
Revenue 1Y (TTM)1.18%
Revenue growth 3Y8.16%
Revenue growth 5Y11.49%
Sales Q2Q%-10.25%

3.2 Future

Based on estimates for the next years, MSGS will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.39% on average per year.
The Revenue is expected to grow by 2.85% on average over the next years.
EPS Next Y54.27%
EPS Next 2Y43.27%
EPS Next 3Y17.39%
EPS Next 5YN/A
Revenue Next Year1.38%
Revenue Next 2Y3.02%
Revenue Next 3Y2.85%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MSGS Yearly Revenue VS EstimatesMSGS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B 1.5B
MSGS Yearly EPS VS EstimatesMSGS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 4 -4 6 -6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

MSGS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MSGS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MSGS Price Earnings VS Forward Price EarningsMSGS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300 -400

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MSGS is on the same level as its industry peers.
Based on the Price/Free Cash Flow ratio, MSGS is valued a bit cheaper than 63.29% of the companies in the same industry.
Industry RankSector Rank
P/FCF 53.45
EV/EBITDA 267.67
MSGS Per share dataMSGS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40

4.3 Compensation for Growth

MSGS's earnings are expected to grow with 17.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.27%
EPS Next 3Y17.39%

More info and screens

0

5. Dividend

5.1 Amount

MSGS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MADISON SQUARE GARDEN SPORTS

NYSE:MSGS (9/2/2025, 8:20:12 PM)

Premarket: 196.47 +0.69 (+0.35%)

195.78

-2.06 (-1.04%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryEntertainment
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)10-30 2025-10-30/bmo
Inst Owners76.42%
Inst Owner ChangeN/A
Ins Owners2.24%
Ins Owner Change-10.37%
Market Cap4.70B
Analysts80
Price Target250.06 (27.72%)
Short Float %4.59%
Short Ratio3.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.03
Dividend Growth(5Y)N/A
DP-2.82%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-50.91%
Min EPS beat(2)-141.27%
Max EPS beat(2)39.44%
EPS beat(4)2
Avg EPS beat(4)-30.23%
Min EPS beat(4)-141.27%
Max EPS beat(4)64.86%
EPS beat(8)5
Avg EPS beat(8)9.74%
EPS beat(12)7
Avg EPS beat(12)-6.54%
EPS beat(16)9
Avg EPS beat(16)15.93%
Revenue beat(2)1
Avg Revenue beat(2)13.16%
Min Revenue beat(2)-3.05%
Max Revenue beat(2)29.38%
Revenue beat(4)2
Avg Revenue beat(4)11.36%
Min Revenue beat(4)-3.05%
Max Revenue beat(4)29.38%
Revenue beat(8)5
Avg Revenue beat(8)18.35%
Revenue beat(12)9
Avg Revenue beat(12)14.8%
Revenue beat(16)10
Avg Revenue beat(16)12.59%
PT rev (1m)-0.67%
PT rev (3m)-0.26%
EPS NQ rev (1m)-30.65%
EPS NQ rev (3m)-104.25%
EPS NY rev (1m)-150.32%
EPS NY rev (3m)-125.24%
Revenue NQ rev (1m)-15.53%
Revenue NQ rev (3m)-25.31%
Revenue NY rev (1m)-2.84%
Revenue NY rev (3m)-3.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.53
P/FCF 53.45
P/OCF 51.33
P/B N/A
P/tB N/A
EV/EBITDA 267.67
EPS(TTM)-0.92
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)3.66
FCFY1.87%
OCF(TTM)3.81
OCFY1.95%
SpS43.26
BVpS-11.72
TBVpS-25.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.52%
ROE N/A
ROCE 1.63%
ROIC 1.25%
ROICexc 1.48%
ROICexgc 2.55%
OM 1.42%
PM (TTM) N/A
GM 33.84%
FCFM 8.47%
ROA(3y)2.11%
ROA(5y)1.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.74%
ROIC(5y)N/A
ROICexc(3y)8.5%
ROICexc(5y)N/A
ROICexgc(3y)14.98%
ROICexgc(5y)N/A
ROCE(3y)10.02%
ROCE(5y)N/A
ROICexcg growth 3Y-45.45%
ROICexcg growth 5YN/A
ROICexc growth 3Y-44.77%
ROICexc growth 5YN/A
OM growth 3Y-48.58%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.62%
GM growth 5Y-3.48%
F-Score4
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.31
Debt/EBITDA 16.14
Cap/Depr 112.52%
Cap/Sales 0.35%
Interest Coverage 250
Cash Conversion 508.19%
Profit Quality N/A
Current Ratio 0.45
Quick Ratio 0.45
Altman-Z 1.96
F-Score4
WACC8.58%
ROIC/WACC0.15
Cap/Depr(3y)91.68%
Cap/Depr(5y)60.4%
Cap/Sales(3y)0.32%
Cap/Sales(5y)0.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-137.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-106.6%
EPS Next Y54.27%
EPS Next 2Y43.27%
EPS Next 3Y17.39%
EPS Next 5YN/A
Revenue 1Y (TTM)1.18%
Revenue growth 3Y8.16%
Revenue growth 5Y11.49%
Sales Q2Q%-10.25%
Revenue Next Year1.38%
Revenue Next 2Y3.02%
Revenue Next 3Y2.85%
Revenue Next 5YN/A
EBIT growth 1Y-89.85%
EBIT growth 3Y-44.39%
EBIT growth 5YN/A
EBIT Next Year112.25%
EBIT Next 3Y-30.01%
EBIT Next 5YN/A
FCF growth 1Y-2.97%
FCF growth 3Y-20.81%
FCF growth 5YN/A
OCF growth 1Y-0.57%
OCF growth 3Y-19.88%
OCF growth 5Y91.04%